Alvaro Moreno-Aspitia
Overview
Explore the profile of Alvaro Moreno-Aspitia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chumsri S, Larson J, Liu E, Tenner K, Adams D, Weidner M, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40053697
Purpose: Activation of the RAS/MAPK pathway is associated with reduced tumor-infiltrating lymphocytes and poor outcomes in triple-negative breast cancer (TNBC). Previous studies demonstrated that inhibition of the MAPK pathway with...
2.
Chumsri S, Pai T, Ma Y, Li Z, Gil A, Moreno-Aspitia A, et al.
J Natl Compr Canc Netw
. 2024 Aug;
22(7):463-468.
PMID: 39191270
Background: The Clinical Treatment Score post-5 years (CTS5) is a risk stratification tool used to determine the risk of late recurrence in hormone receptor-positive (HR+), HER2-negative breast cancer (BC). Limited...
3.
Martins-Branco D, Kassapian M, Debien V, Caparica R, Eiger D, Dafni U, et al.
Breast Cancer Res Treat
. 2023 Nov;
203(3):497-509.
PMID: 37938495
Purpose: To assess whether erythropoiesis-stimulating agents (ESA) administration impacts the outcomes of patients with HER2-positive early breast cancer (EBC). Methods: ALTTO (NCT00490139) patients were categorized by ESA use during adjuvant...
4.
Huang K, Jakub J, Gabriel E, Moreno-Aspitia A, McLaughlin S
Ann Surg Oncol
. 2023 Jul;
30(12):7026-7035.
PMID: 37490162
Background: The purpose of this study was to compare the overall survival (OS) of upfront surgery followed by adjuvant chemotherapy (ACT) versus neoadjuvant chemotherapy (NACT) followed by surgery in patients...
5.
Blau S, Peguero J, Moore H, Anderson I, Barve M, Cherian M, et al.
JCO Clin Cancer Inform
. 2023 Jun;
7:e2200164.
PMID: 37352479
Purpose: There are numerous barriers to enrollment in oncology biomarker-driven studies. Methods: The ELAINE 2 study (ClinicalTrials.gov identifier: NCT04432454) is an open-label phase 2 study of lasofoxifene combined with abemaciclib...
6.
Ademuyiwa F, Gao F, Street C, Chen I, Northfelt D, Wesolowski R, et al.
NPJ Breast Cancer
. 2022 Dec;
8(1):134.
PMID: 36585404
Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients with metastatic PD-L1 positive triple negative breast cancer (TNBC). Atezolizumab with anthracycline- and taxane-based neoadjuvant chemotherapy has also...
7.
Berrian J, Liu Y, Ezenwajiaku N, Moreno-Aspitia A, Holton S, Toriola A, et al.
Cancer Med
. 2022 Nov;
12(6):7381-7388.
PMID: 36404491
Purpose: To determine if the COVID-19 pandemic has further exacerbated racial disparities in late-stage presentation of breast, colorectal, lung, and prostate cancers. Methods: We conducted a registry-based retrospective study of...
8.
Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, et al.
Br J Cancer
. 2022 Sep;
127(10):1799-1807.
PMID: 36050448
Background: Patients with small node-negative HER2-positive breast cancer are commonly treated with paclitaxel and 1 year of adjuvant trastuzumab. We performed a sub-analysis of the ALTTO trial to explore the...
9.
Agostinetto E, Ameye L, Martel S, Aftimos P, Ponde N, Maurer C, et al.
NPJ Breast Cancer
. 2022 Jul;
8(1):87.
PMID: 35859079
The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. Therefore, we investigated...
10.
Chumsri S, Li Z, Serie D, Norton N, Mashadi-Hossein A, Tenner K, et al.
NPJ Breast Cancer
. 2022 May;
8(1):68.
PMID: 35610260
Trastuzumab acts in part through the adaptive immune system. Previous studies showed that enrichment of immune-related gene expression was associated with improved outcomes in HER2-positive (HER2+) breast cancer. However, the...